Tacey X. Viegas

Mirna Therapeutics (United States) — United States

Materials Science · Physical Sciences

11h-index1.1kcitations26works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

biodegradable polymer synthesis and properties(6), Synthesis and properties of polymers(4), Advancements in Transdermal Drug Delivery(3), Nanoparticle-Based Drug Delivery(2), Parkinson's Disease Mechanisms and Treatments(2)

Publications25 total

<scp>Once‐Weekly</scp> Subcutaneous Delivery of <scp>Polymer‐Linked</scp> Rotigotine (<scp>SER</scp>‐214) Provides Continuous Plasma Levels in Parkinson's Disease Patients
Movement Disorders·2020· 47 cited
Tuning drug release from polyoxazoline-drug conjugates
European Polymer Journal·2019· 49 cited
Poly(oxazolines)
Elsevier eBooks·2018· 18 cited
List of contributors
Elsevier eBooks·2018
Poly(2‐Oxazoline) Polymers – Synthesis, Characterization, and Applications in Development of POZ Therapeutics
2017· 3 cited
Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson’s disease – Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications
European Polymer Journal·2016· 171 cited
Poly(ethylene glycol)
AccessScience·2015· 36 cited
Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit
Movement Disorders·2013· 67 citedOpen Access
Selective conjugation of poly(2-ethyl 2-oxazoline) to granulocyte colony stimulating factor
Journal of Controlled Release·2012· 80 cited
Polyoxazoline: Chemistry, Properties, and Applications in Drug Delivery
Bioconjugate Chemistry·2011· 418 cited
Regulatory strategy and approval processes considered for PEG-drug conjugates and other nanomedicines
Birkhäuser Basel eBooks·2009· 1 cited
Poly(2-ethyl 2-oxazoline): a promising polymer for protein conjugation
2009
NKTR-102, a novel PEGylated irinotecan, results in sustained tumor growth suppression in mouse models of human colorectal and lung tumors that correlates with increased and sustained tumor SN38 exposure
Molecular Cancer Therapeutics·2007· 5 cited
Polyethylene glycol conjugation of irinotecan improves its antitumor activity in three mouse xenograft models
Molecular Cancer Therapeutics·2007· 2 cited
722 POSTER Antitumor activity and pharmacokinetics of a novel PEGylated irinotecan in irinotecan-resistant colorectal tumours implanted in mice
European Journal of Cancer Supplements·2007· 4 cited
REMOVED: Physicochemical properties of the potent influenza neuraminidase inhibitor, peramivir (BCX-1812)
Journal of Pharmaceutical and Biomedical Analysis·2007
Poly(ethylene) Glycol Conjugates of Biopharmaceuticals in Drug Delivery
2005· 6 cited
Intrinsic Drug Dissolution Testing Using the Stationary Disk System
Dissolution Technologies·2001· 10 citedOpen Access
Pharmacokinetics and Pharmacodynamics of Peldesine (BCX‐34), a Purine Nucleoside Phosphorylase Inhibitor, following Single and Multiple Oral Doses in Healthy Volunteers
The Journal of Clinical Pharmacology·2000· 40 cited
Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules
International Journal of Pharmaceutics·1999· 34 cited
page 1 of 2Next →

Frequent Co-authors

Michael D. Bentley(7), Zhihao Fang(7), Kunsang Yoon(6), Bekir Dizman(6), Rebecca Weimer(6), Randall W. Moreadith(5), J. Milton Harris(4), Anna Mero(3), Gianfranco Pasut(3), Francesco M. Veronese(3), David G. Standaert(3), Ahmed H. Hikal(3), Carl‐Michael Staschen(3), Alan Jones(2), Michael A. Eldon(2), Robert W. Cleary(2), Lida Antonian(2), Brendan P. Rae(1), Xiuling Li(1), Christoph Rader(1)